About SCA3 Spinocerebellar ataxia type 3 (SCA3) is a rare neuromuscular disease with a prevalence of one to five in 100,000 people. It is the most common form of spinocerebellar ataxia.

However, due to the lack of statistical significance, larger and more robust Phase III trials are necessary ... L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised ...

Autosomal dominant cerebellar ataxia type III (ADCA III) is a relatively benign, late-onset, slowly progressive neurological disorder characterized by an uncomplicated cerebellar syndrome.

These programs target spinocerebellar ataxia type 1, spinocerebellar ataxia type 3 and Huntington's disease. As part of this deal, the companies have also formed a discovery collaboration under ...

Considering taking supplements to treat spinocerebellar ataxia sca? Below is a list of common natural remedies used to treat or reduce the symptoms of spinocerebellar ataxia sca. Follow the links ...

Genetic analysis beyond the causative variants, and independent of the core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach phenotypic variability.

Spinocerebellar Ataxia (SCA) is a rare ... disease progression on the primary and secondary outcome measures at the 3-year endpoint in a real-world evidence (RWE) study. Troriluzole has a well ...

Find effective medications for 'Spinocerebellar Ataxia treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia ...